Grants Available for CVD and Diabetes Projects

The TTRA supports projects that advance an innovative drug or device towards commercial proof-of-concept for an unmet need for cardiovascular disease (CVD) or complications of diabetes (type 1 or 2).

The TTRA particularly seeks to fund:

• Pre-clinical Investigational New Drug (IND)-enabling studies, including safety and dosing
• Prototype refinement and product testing
• Clinical trials
• Regulatory support.

Funding is available across two streams:

• Drugs: Innovative pharmaceutical drugs (e.g. small molecules, antibodies, cell/gene therapies, vaccines etc)
• Devices: Medical devices to prevent, diagnose, treat or manage disease.

The total pool is $28.5 million.

Grants of between $200,000 and $1.5 million will be available, and cover between 50-80% of costs, depending on grant request size.

An applicant must be:

an Australian-based for-profit start-ups, spin-outs and SMEs which:

• Are incorporated in Australia
• Have an ABN
• Have less than 200 employees
• Control or have legal right to access all existing/potential project IP
• Are not a university or research institute technology transfer office.

Projects must involve either a:

• Drug at or beyond pre-clinical development stage; or
• Device at or beyond TRL4 (technical proof-of-concept and safety demonstrated in laboratory).

Note: Applicants cannot request funding towards contract research for a third party.

Expressions of Interest close on 4 November 2024.